Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine

Journal of Pediatrics

Volumn 149, Issue 5, 2006, Pages

  Zepp, Fred ^a   Knuf, Markus ^a   Habermehl, Pirmin ^a   Mannhardt Laakmann, Wilma ^a   Howe, Barbara ^a   Friedland, Leonard R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; PAC MERIEUX; PERTUSSIS VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ANTIGEN DETECTION; ARTHRALGIA; ARTICLE; BLOODY DIARRHEA; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INCIDENCE; INFECTION; INJECTION SITE SWELLING; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SKIN INDURATION; SKIN REDNESS; SWELLING; VACCINATION; VOMITING;

EID: 33750618038     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.06.016     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention. Pertussis: United States, 2001-2003. MMWR 2005;54:1283-6.
2. Guris D., Strebel P.M., Bardenheier B., Brennan M., Tachdjian R., Finch E., et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 28 (1999) 1230-1237
3. Pertussis Surveillance Report: 8/12/05. Bacterial Vaccine Preventable Diseases Branch, National Immunization Program, Centers for Disease Control and Prevention. 2004: Atlanta, GA (final data).
4. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infec Dis J 24 (2005) S104-S108
5. US Food and Drug Administration Center for Biologics Evaluation and Research. Product approval information: licensing action. [updated 2005 May 17; 2005 June 10]. Available from http://www.fda.gov/cber/products/tdapgla050305.htm
6. Rennels M.B., Deloria M.A., Pichichero M.E., Losonsky G.A., Englund J.A., Meade B.D., et al. Extensive swelling reactions occurring after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics (2000) 105. http://www.pediatrics.org/cgi/content/full/105/1/e12 Available from http://www.pediatrics.org/cgi/content/full/105/1/e12
7. GlaxoSmithKline Biologicals. Rixensart, Belgium. Infanrix® package insert.
8. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices and the American Academy of Family Physicians. MMWR Morb Mortal Wkly Rep 51 RR-2 (2002) 1-35
9. Keitel W.A., Muenz L.R., Decker M.D., Englund J.A., Mink C.M., Blumberg D.A., et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 180 (1999) 397-403
10. Pichichero M.E., Blatter M.M., Kennedy W.A., Hedrick J., Descamps D., and Friedland L.R. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 117 (2006) 1084-1093
11. Tran Minh N.N., He Q., Ramalho A., Kaufhold A., Viljanen M.K., Arvilommi H., et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics (1999) 104. http://www.pediatrics.org/cgi/content/full/104/6/e70 Available from http://www.pediatrics.org/cgi/content/full/104/6/e70
12. Theeten H., Van Damme P., Hoppenbrouwers K., Leback E., Sokal E., Wolter J., et al. Effects of lowering the aluminium content of a dTap vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine 23 (2005) 1515-1521
13. Pichichero M.E., Rennels M.B., Edwards K.M., Blatter M.M., Marshall G.S., Bologa M., et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 293 (2005) 3003-3011
14. GlaxoSmithKline Biologicals. Rixensart, Belgium. Boostrix® package insert.
15. GlaxoSmithKline Biologicals. Rixensart, Belgium. Havrix® package insert.
16. Saenger R, Wolter J, Schuerman L. A reduced-antigen diphtheria-tetanus-acellular pertussis-IPV vaccine for booster vaccination of 4 to 8 year old children. 21stAnnual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). April 9-11, 2003, Taormina, Sicily. Abstract No. 247.
17. Woo E.J., Burwen D.R., Gatumu S.N., and Ball R. Vaccine Adverse Event Reporting System Working Group: consecutive dose of a five-component acellular pertussis-based combination vaccine. Clin Infect Dis 37 (2003) 351-358
18. Rennels M.B. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis 14 (2003) 196-198
19. Tozzi A.E., Anemona A., Stefanelli P., Salmaso S., Ciofi degli Atti M., Mastrantonio P., et al. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics (2001) 107. http://www.pediatrics.org/cgi/content/full/107/2/e25 Available from http://www.pediatrics.org/cgi/content/full/107/2/e25
20. Pichichero M.E. Acellular pertussis vaccines: towards an improved safety profile. Drug Saf 15 (1996) 311-324
21. Pichichero M.E., Edwards K.M., Anderson E.L., Rennels M., Englund J., Yerg D., et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics (2000) 105. http://www.pediatrics.org/cgi/content/full/105/1/e11 Available from http://www.pediatrics.org/cgi/content/full/105/1/e11
22. Skowronski D.M., Remple V.P., Macnabb J., Pielak K., Patrick D., Halperin S., et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics (2003) 112. http://www.pediatrics.org/cgi/content/full/112/6/e453 Available from http://www.pediatrics.org/cgi/content/full/112/6/e453
23. Centers for Disease Control. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 49 RR-13 (2000) 1-8
24. Campins-Marti M., Cheng H.K., Forsyth K., Guiso N., Halperin S., Huang L.M., et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20 (2001) 641-646
25. Hewlett E.L., and Edwards K.M. Clinical practice: pertussis: not just for kids. N Engl J Med 352 (2005) 1215-1222
26. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine. Pediatrics 117 (2006) 965-978